-$0.07 Earnings Per Share Expected for ENDRA Life Sciences Inc. (NASDAQ:NDRA) This Quarter

Analysts forecast that ENDRA Life Sciences Inc. (NASDAQ:NDRAGet Rating) will announce ($0.07) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for ENDRA Life Sciences’ earnings. ENDRA Life Sciences posted earnings of ($0.08) per share in the same quarter last year, which would indicate a positive year over year growth rate of 12.5%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that ENDRA Life Sciences will report full year earnings of ($0.26) per share for the current year. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover ENDRA Life Sciences.

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) last released its earnings results on Wednesday, March 30th. The company reported ($0.07) EPS for the quarter. During the same quarter in the previous year, the business posted ($0.10) earnings per share.

Several research firms recently commented on NDRA. Zacks Investment Research upgraded ENDRA Life Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. HC Wainwright dropped their target price on ENDRA Life Sciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, April 7th.

Large investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in ENDRA Life Sciences during the third quarter worth about $26,000. Royal Bank of Canada increased its stake in ENDRA Life Sciences by 65.3% during the second quarter. Royal Bank of Canada now owns 25,310 shares of the company’s stock worth $55,000 after acquiring an additional 10,000 shares during the last quarter. Raymond James & Associates purchased a new stake in shares of ENDRA Life Sciences in the fourth quarter worth about $49,000. Virtu Financial LLC purchased a new stake in shares of ENDRA Life Sciences in the fourth quarter worth about $50,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of ENDRA Life Sciences in the fourth quarter worth about $150,000. Institutional investors own 10.03% of the company’s stock.

ENDRA Life Sciences stock opened at $0.20 on Friday. The firm has a market capitalization of $8.77 million, a P/E ratio of -0.74 and a beta of 1.40. The stock has a fifty day moving average price of $0.32 and a 200 day moving average price of $0.62. ENDRA Life Sciences has a 52 week low of $0.18 and a 52 week high of $2.44.

About ENDRA Life Sciences (Get Rating)

ENDRA Life Sciences Inc develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.

Featured Articles

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.